<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216681</url>
  </required_header>
  <id_info>
    <org_study_id>HHNN-01</org_study_id>
    <nct_id>NCT03216681</nct_id>
  </id_info>
  <brief_title>Hoat Huyet Nhat Nhat Versus Tanakan for Treatment of Symptoms Related to the Insufficient Blood Supply to the Brain</brief_title>
  <official_title>An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nhat Nhat Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nhat Nhat Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Hoat Huyet Nhat Nhat on the
      reduction of common symptoms related to the insufficient blood supply to the brain such as
      headache, vertigo, dizziness, sleep disorders and forgetfulness; compared with Gingko Biloba
      Egb761 (Tanakan) after 45 days of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with symptoms related to the insufficient blood supply to the brain recovered after 45 days of treatment as assessed by Symptom Improvement Likert Scale in Hoat Huyet Nhat Nhat and Tanakan 40mg group</measure>
    <time_frame>45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of headache symptom in patients with symptoms related to the insufficient blood supply to the brain as assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of vertigo symptom in patients with symptoms related to the insufficient blood supply to the brain as assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of dizziness symptom in patients with symptoms related to the insufficient blood supply to the brain as assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of sleep disorders symptom in patients with symptoms related to the insufficient blood supply to the brain as assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of forgetfulness symptom in patients with symptoms related to the insufficient blood supply to the brain as assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 45 days of the severity of all symptoms related to the insufficient blood supply to the brain as assessed by Khadjev Score</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with clinically significant vital sign parameters at Day 45.</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with clinically significant laboratory parameters at Day 45.</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Insufficient Blood Supply to the Brain</condition>
  <arm_group>
    <arm_group_label>Hoat Huyet Nhat Nhat</arm_group_label>
    <description>Administered orally twice a day, 2 tablets each time, for 45 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanakan 40mg</arm_group_label>
    <description>Administered orally three times a day, one tablet each time, for 45 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hoat Huyet Nhat Nhat</intervention_name>
    <description>Administered orally twice a day, 2 tablets each time, for 45 days.</description>
    <arm_group_label>Hoat Huyet Nhat Nhat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanakan 40mg</intervention_name>
    <description>Administered orally three times a day, 1 tablet each time, for 45 days.</description>
    <arm_group_label>Tanakan 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with symptoms related to the insufficient blood supply to the
        brain.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female more than 18 year old.

          -  With at least one of the symptoms related to the insufficient blood supply to the
             brain scored more than 5 out 10, on the Visual Analog Scale.

          -  Patients who will be using either Hoat Huyet Nhat Nhat or Tanakan following doctor's
             prescription or by patients own decision.

          -  Sign the informed consent form

        Exclusion Criteria:

          -  Use of any medications for treatment of the insufficient blood supply to the brain in
             the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pham Ngoc Hung, PhD</last_name>
    <phone>84.989057989</phone>
    <email>pnhungqy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tran Phuong</last_name>
    <phone>84.24.35 62 5766</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vietnam Military Medical University</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pham Ngoc Hung, PhD.</last_name>
      <phone>84.989057989</phone>
      <email>pnhungqy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

